NCT06833619 Efficacy of Endoscopic Ultrasound Guided Liver Biopsy Using Dynamic Wet Technique
| NCT ID | NCT06833619 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sohag University |
| Condition | Efficacy of Endoscopic Ultrasound Guided Liver Biopsy Using Dynamic Wet Technique |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-12-01 |
| Primary Completion | 2026-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2024-12-01 with a primary completion date of 2026-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Endoscopic ultrasound-guided liver biopsy (EUS-LB) can overcome many shortcomings of percutaneous liver biopsy and TJLB. Targeted and non-targeted liver biopsies can be done through this biopsy. It can be done in patients with international normalized ratio (INR) up to 2. It has less tissue fragmentation compared with TJLB. Needle entering the liver can be viewed in real-time (intrahepatic vessels and bile duct can be spared from injury) (Sharma et al., 2023). Both lobes of the liver can be accessed. It provides minimal patient discomfort. EUS-LB can access liver lesions that may not be safely accessible by routine US or computed tomography (tenBerge et al., 2002). It provides better results in obese individuals compared with percutaneous liver biopsy. It is safe in pregnant females requiring liver biopsy (Khare et al., 2024). Despite these advantages, EUS-LB is largely limited to tertiary care centers and its use is not yet widespread. This may be because, since its inception, numerous variations in needle shape, needle size, and, most notably, sampling techniques have been adopted. However, no consensus protocol for acquisition has been recognized, leading to poor procedural standardization and wide ranges of reported outcomes in sample quality and diagnostic yield. As such, there is a substantial need for a uniform technique that will safely maximize diagnostic performance with minimal needle passes (Khare et al., 2024).
Eligibility Criteria
Inclusion Criteria: * The participants of the study were adults in need of liver biopsy for the evaluation of Altered liver function test Exclusion Criteria: * Using anti-platelets or anticoagulants within the last 5days * Inability to provide informed consent * Moderate-to-gross ascites * Child C cirrhosis * INR more than 2.01 * Platelet count less than 50,000/µL3
Contact & Investigator
Sara Elbadry Eirabie, master
STUDY DIRECTOR
Sohag
Frequently Asked Questions
Who can join the NCT06833619 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Efficacy of Endoscopic Ultrasound Guided Liver Biopsy Using Dynamic Wet Technique. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06833619 currently recruiting?
Yes, NCT06833619 is actively recruiting participants. Contact the research team at elbadrysara615@gmail.com for enrollment information.
Where is the NCT06833619 trial being conducted?
This trial is being conducted at Sohag, Egypt.
Who is sponsoring the NCT06833619 clinical trial?
NCT06833619 is sponsored by Sohag University. The principal investigator is Sara Elbadry Eirabie, master at Sohag. The trial plans to enroll 30 participants.